United Therapeutics | UTHR - Operating Profit


United Therapeutics reported $325.8M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Amarin USD -2.26M 564K Dec/2025
Ardelyx USD 5.1M 431K Dec/2025
Baxter International USD 66M 280.2M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Emergent BioSolutions USD -218M 69.9M Jun/2023
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026